HCPCS Level II code J7330 identifies an autologous cultured chondrocytes implant, a regenerative orthopedic therapy that uses a patient’s own cartilage cells to repair focal articular cartilage defects. The code is clinically significant due to the specialized manufacturing, surgical implantation process, and implications for coverage policy and utilization management across payers. Nationally, this therapy factors into discussions about advanced biologic implants, surgical outcomes, and cost-effectiveness for focal cartilage repair.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code represents, common payer approaches to coverage and prior authorization, and service-line considerations for hospitals and ambulatory surgical centers. The publication summarizes expected sites of service, clinical context for use in orthopedic surgery, and common billing modifiers and claim considerations when data are available. Benchmarks, policy updates, and payer-specific guidance are presented where available; if payer-specific details are not provided, the section will note: "Data not available in the input."

This summary is written for a national audience seeking concise guidance on how HCPCS Level II code J7330 fits into clinical practice, coding workflows, and payer interactions for advanced cartilage repair procedures.